Drug

Alendronate

In clinical development

Emerging researchLate-stage developmentSteady momentum

Also known as Binosto, Fosamax, Fosamax Plus D.

RxNorm46041 ChEMBLCHEMBL870 ATCM05BA04UNIIX1J18R4W8P

Research papers

Active clinical trials

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Small Trial of Alendronate Impact on the Reservoir of HIV

Clinical trial2026-06-10Results expected Q1 2027 · ClinicalTrials.gov

Novel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover

Clinical trial2026-05-14Results expected Q1 2027 · ClinicalTrials.gov

Novel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover - Follow Up Study

Clinical trial2026-04-01Results expected Q4 2029 · ClinicalTrials.gov

A Multicenter, Randomized, Controlled, Blinded, Phase II Clinical Study to Evaluate the Efficacy, Safety, Tolerability, and PK/PD Profiles of RAB001 for Injection in Patients With Early-stage Non-traumatic Osteonecrosis Caused by Long-term Glucocorticoid Use.（LLP2A-Alendronate）

Clinical trial2026-03-24Results expected Q4 2026 · ClinicalTrials.gov

Effects of Denosumab on Bone Mineral Density, Markers of Bone Metabolism and Bone Microarchitecture in Women With Anorexia Nervosa: A Pilot Study

Clinical trial2025-11-04Results posted · ClinicalTrials.gov

The Effect of Oral Administration of Alendronate on Knee Functions Following Anterior Cruciate Ligament Reconstruction - A Pilot Study of Single-Blind Randomized Controlled Trial

Clinical trial2025-10-31Primary completion · ClinicalTrials.gov

Effects of Romosozumab on Bone Health in Women With Spinal Cord Injury and Osteoporosis

Clinical trial2025-09-24Results posted · ClinicalTrials.gov

A Multicenter, International, Randomized, Double-blind, Alendronate-controlled Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis

Clinical trial2025-02-21Results posted · ClinicalTrials.gov

Bone Mineral Density After Transitioning From Denosumab to Alendronate.

Research2020-03-01The Journal of clinical endocrinology and metabolism

ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis.

Research2018-08-01The Journal of clinical endocrinology and metabolism

Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial.

Research2017-02-01Mayo Clinic proceedings

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.

Research2010-01-01Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Alendronate

Aliases & brands

BinostoFosamaxFosamax Plus D

RxNorm CUI

46041

ChEMBL ID

CHEMBL870

ATC codes

M05BA04

UNII

X1J18R4W8P

Clinical trials

90 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme

CLINICALTRIALS.GOV · LIVE REGISTRY

registered trials across all phases

LATEST COMPLETION 2024

Active studies

Recruiting

Late-stage (III+)

Completed

Discontinued

PHASE DISTRIBUTIONn = 90

Phase 14Phase 225Phase 2 / 36Phase 323Phase 426Phase N / A6

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Novel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover - Follow Up Study

Enrolling by invitationPH IVPaul F Netzeln=402029

Novel Precision Medicine Approach to Treatment of Osteoporosis Based on Bone Turnover

Active, not recruitingPH IVMadhumathi Raon=602027

The Effect of Oral Administration of Alendronate on Knee Functions Following Anterior Cruciate Ligament Reconstruction - A Pilot Study of Single-Blind Randomized Controlled Trial

Unknown statusPH IVChinese University of Hong Kongn=642025

Efficacy and Safety of Minodronate in the Treatment of Postmenopausal Osteoporosis With Low Back Pain: a Single-centre and Randomized Controlled Trial

Unknown statusPH IVPeking University Third Hospitaln=722024

Comparative Antiresorptive Efficacy of Alendronate or Raloxifene Following Discontinuation of Denosumab

Active, not recruitingPH IVMassachusetts General Hospitaln=512023

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Clinical Study to Evaluate the Effect of MK-0616 on the Pharmacokinetics of Alendronate in Healthy Adult Participants

CompletedPH IMerck Sharp & Dohme LLCn=362024

Effects of Romosozumab on Bone Health in Women With Spinal Cord Injury and Osteoporosis

CompletedPH IINorthwestern Universityn=122024

A Multicenter, Randomized, Open-label, Parallel Controlled, Phase Ⅲ Clinical Study to Evaluate the Efficacy and Safety of SAL056 (Teriparatide for Injection ) in the Treatment of Postmenopausal Women With Osteoporosis at High Fracture Risk

CompletedPH IIIShenzhen Salubris Pharmaceuticals Co., Ltd.n=4932024

Bisphosphonates for Prevention of Post-Denosumab Bone Loss in Premenopausal Women With Idiopathic Osteoporosis

CompletedPH IIColumbia Universityn=242023

Alendronate Treatment of Osteoporosis in Rheumatoid Arthritis - Indication and Duration: A Randomized, Double-blind, Placebocontrolled Study to Evaluate the Effects of Discontinuation of Alendronate in Patients With Both Rheumatoid Arthritis and Low Bone Mass

CompletedPH IIUniversity of Aarhusn=692021

Effects of Denosumab on Bone Mineral Density, Markers of Bone Metabolism and Bone Microarchitecture in Women With Anorexia Nervosa: A Pilot Study

CompletedPH IIIMassachusetts General Hospitaln=302021

Research activity

10 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time

20042020

Most influential

Ten years' experience with alendronate for osteoporosis in postmenopausal women.

The New England journal of medicine · 2004 · 840 cites

Denosumab in postmenopausal women with low bone mineral density.

The New England journal of medicine · 2006 · 794 cites

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial.

Bone · 2008 · 388 cites

Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2009 · 383 cites

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2010 · 271 cites

Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2007 · 217 cites